Wonder what's real.
Plain-English reads on the health and science topics people are talking about: what it is, what's actually been shown, and what's still open. The studies are always one tap away, never in your way.
Your curiosity is enough. Evidence determines the answer.
Get a plain-English read when the evidence changes.
On GLP-1s and other hot topics (GLP-1 medicines, Semaglutide). We only write when our read meaningfully changes. Pick more topics any time.
Tracking now
What's getting attention on Wondara right now. Coverage and Watch interest are attention — not proof.
GLP-1 medicines
4 recent stories · latest from NPR, Oct 10, 2026
Open topic →Word on the streetRetatrutide
4 recent stories · latest from The Washington Post, Oct 9, 2026
Open topic →Word on the streetSemaglutide
4 recent stories · latest from Reuters, Sep 30, 2026
Open topic →Word on the streetTirzepatide
3 recent stories · latest from STAT, Sep 30, 2026
Open topic →Word on the streetOrforglipron
4 recent stories · latest from Reuters, Sep 29, 2026
Open topic →Word on the streetPsilocybin
4 recent stories · latest from The Washington Post, Sep 17, 2026
Open topic →Getting attentionGLP-1 medicines
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Getting attentionOrforglipron
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Getting attentionPsilocybin
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Getting attentionRetatrutide
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Getting attentionSemaglutide
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Getting attentionTirzepatide
Hot, and we haven't assessed the evidence yet. · Editor-assessed attention
See the gap →Word on the street
The topics getting news coverage right now, and our plain-English read on each. Coverage means people are talking; it isn't proof.
GLP-1 medicines
4 recent stories · latest from NPR, Oct 10, 2026
Get the short version →Retatrutide
4 recent stories · latest from The Washington Post, Oct 9, 2026
Get the short version →Semaglutide
4 recent stories · latest from Reuters, Sep 30, 2026
Get the short version →Tirzepatide
3 recent stories · latest from STAT, Sep 30, 2026
Get the short version →Orforglipron
4 recent stories · latest from Reuters, Sep 29, 2026
Get the short version →Psilocybin
4 recent stories · latest from The Washington Post, Sep 17, 2026
Get the short version →No new reviewed changes to report.
New information only makes this list after it clears the publication and source-review gates. Quiet is a valid state.
The gap is the story.
A claim may be getting attention without stronger evidence. The reverse can also happen. We show the difference instead of converting either into a fake score.
How evidence is assessed →What still isn't settled?
The next worthwhile discovery begins by being precise about what is missing.
Ketamine
For adults with treatment-resistant depression, is IV ketamine as effective as FDA-approved esketamine nasal spray?
Explore this question →compoundMetformin
Does metformin slow aging or prevent age-related disease in people without diabetes?
Explore this question →compoundSemaglutide
For adults with obesity but no established cardiovascular disease, does semaglutide prevent a first heart attack or stroke?
Explore this question →Pick what matters. Watch what changes.
Pick as many research topics as you like. One email confirms them all.
Reviewed topics
Pages an editor has reviewed and published: editor picks first, then newest review. Reviewed means the page and its claims were checked against cited sources; it does not establish effectiveness, safety or an attention trend.
Methylene blue
Reviewed page · reviewed Oct 11, 2026 · 8 linked sourcesSemaglutide
Reviewed page · reviewed Oct 11, 2026 · 27 linked sourcesTirzepatide
Reviewed page · reviewed Oct 11, 2026 · 19 linked sourcesKetamine
Reviewed page · reviewed Oct 11, 2026 · 9 linked sourcesPsilocybin
Reviewed page · reviewed Oct 11, 2026 · 13 linked sourcesFunctional mushrooms
Reviewed page · reviewed Oct 11, 2026 · 7 linked sourcesRetatrutide
Reviewed page · reviewed Oct 11, 2026 · 14 linked sourcesTestosterone
Reviewed page · reviewed Oct 11, 2026 · 10 linked sourcesSirolimus
Reviewed page · reviewed Oct 11, 2026 · 8 linked sourcesNicotinamide mononucleotide
Reviewed page · reviewed Oct 11, 2026 · 8 linked sourcesNAD+
Reviewed page · reviewed Oct 11, 2026 · 7 linked sourcesMetformin
Reviewed page · reviewed Oct 11, 2026 · 9 linked sourcesWatch, don't bookmark
Follow a research question and see meaningful, reviewed changes when they're available.
Separate attention from evidence
What's popular and what research supports are different things.
Inspect the sources
Open the original receipts rather than relying on a headline.
See what changed
Corrections and changes in conclusions belong on the record.
Participate responsibly
Share questions and observations without confusing experience for proof.
You can fund the question. You can't buy the answer.
Conflicts and funding must be visible. We are building the governance and research partnerships required to make that commitment verifiable; independent oversight is not yet operating.
Read our story and disclosure →